Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals

NCT05786937 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

HIV Vaccine

Interventions

BIOLOGICAL: Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides
BIOLOGICAL: Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides
OTHER: Commercial ringer´s lactate solution

Sponsor

University of Sao Paulo General Hospital